impact view view guidanc larg line
revenu adj ep slightli prior mse adj ebitda slightli higher
organ growth guidanc line prior estimate
ipreo revenu slightli net interest expens guidanc
higher-than-expect tax rate capital-expenditure midpoint
guidanc impli increas midpoint line
prior expect continu find stock rel expens
standard ev/ebitda premium analyt peer despit
averag top-lin growth rate ntm remain uw follow model
updat rais pt
midpt
midpt
manag expect organ growth mid-
single-digit upstream continu improv
mid- downstream remain strong
transport organ growth expect high-single-digit
driven use car busi auto benefit use car
list continu traction newer market like bank insur
growth maritim aerospac defens
financi servic growth expect mid-single-digit
process flat slightli
growth expect single-digit adjust boiler code
compani trade less week
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
risk/reward unfavor downsid pt
risk/reward unfavor downsid pt
deriv discount cash flow valuat wacc
risk-fre rate market risk premium beta
termin growth rate base case
organ revenu growth compound-annual-growth-rate adj ebitda margin
encompass higher growth rate oper margin base
case full credit target revenu cost synergi
organ revenu growth compound-annual-growth-rate adj ebitda margin
growth lacklust energi environ
continu moder margin benefit scale acquisit synergi
credit half revenu full cost synergi
organ revenu growth compound-annual-growth-rate adj ebitda margin
encompass lower growth across industri vertic especi
lower oper margin base case credit
revenu cost synergi
uw lead supplier
inform servic across multipl
vertic attract busi model
believ current elev valuat
standard ev/ebitda vs
peer adequ reflect
averag organ growth
dcf-base pt impli downsid current
product absenc substitut lead
margin expans driven cost synergi
scale platform initi
develop geograph penetr
capit return repurchas
share ytd though halt
program delev pend ipreo
acquisit reach target
loan issuanc trade volum
auto industri slowdown acceler
risk achiev price
better-than worse-than-expect
exhibit quarterli revenu segment
exhibit statement flow
valuat methodolog risk
price target deriv discount cash flow valuat wacc
risk-fre rate market risk premium beta termin growth
rate base case risk achiev price target includ
better-than worse-than-expect capital-expenditure trend could drive higher/low
